| Contact |
General |
Specializations in Countries |
Contribution to the Global Plan |
Declaration |
View this partner's profile
Organization Contact Information |
| Name: |
Setshaba Research Centre |
| Street 1: |
2088 Block H |
| Street 2: |
Soshanguve |
| City: |
Pretoria |
| Province: |
Gauteng |
| Post Code: |
0152 |
| Country: |
South Africa |
| Phone: |
+27127992422 |
| Organization Email: |
ayman@setshaba.org.za |
| Web Site: |
http://www.setshabaresearchcentre.org.za |
| Other Online Presence: |
|
Focal Point Contact Information |
| Salutation: |
Dr |
| First Name: |
Khatija |
| Last Name: |
Ahmed |
| Title: |
Executive Director |
| Email: |
kahmed@setshaba.org.za |
| Phone: |
+27127992422 |
|
Alternate Focal Point Contact Information |
| Salutation: |
Dr |
| First Name: |
Mookho |
| Last Name: |
Malahleha |
| Title: |
Deputy Directer |
| Email: |
mookho@setshaba.org.za |
| Phone: |
+27127992422 |
|
General Information |
| Board Constituency: |
Developing Country NGO |
| Is your organization legally registered in your country: |
Yes |
| If yes, please enter your registration number: |
|
| Organization Type - Primary: |
Non-Governmental Organization |
| Organization Type - Secondary: |
Community-Based Organization (CBO) |
| Organization Description: |
| Setshaba Research Centre (SRC)is a South African NGO/NPO. Its mission is to conduct relevant, ethical and cost beneficial research studies in collaboration with academic institutions. SRC core focus is HIV prevention studies that aim to reduce the risk of HIV infection.Our interest on Tuberculosis(TB) is motivated by the fact that TB is the leading cause of morbidity and mortality among HIV infected people (our main focus). Additionally, Sub-Saharan Africa accounts for more than 70% of 40 million worldwide live with HIV. SRC has previously conducted study in TB diagnostic and currently hosting vaccine and treatment studies. |
| |
| Do you know about the UNHLM declaration: |
|
Specializations / Areas of Work |
Advocacy
Research and Development
|
Other Organization Information |
| Total number of staff in your organization: |
51 - 99 |
| Number of full-time staff who are directly involved with TB: |
51 - 99 |
| Number of part-time staff who are directly involved with TB: |
1 - 5 |
| Number of volunteers who are directly involved with TB: |
1 - 5 |
| |
| How did you hear about the Stop TB Partnership: |
Stop TB communications |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
| Why do you wish join the Stop TB Partnership: |
Network with other partners |
| |
| Are you a member of a Stop TB national partnership: |
No |
| Are you in contact with your national TB programme: |
Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| SRC contributes towards the South African TB control plan by providing education to the community in addition to health care benefits. |
| |
Geographical Reach |
| Which country is your headquarters located in: |
South Africa |
Which countries do you do operate in:
(This includes countries you are conducting activities in) |
South Africa
|
Contribution |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
New Diagnostics:
SRC has previously conducted completed studies on new TB diagnostics; this includes but not limited to a multicenter study titled “Phase III trial in subjects to have tuberculosis comparing the diagnostic performance of C-TB to Quantiferon-TB Gold In-Tube, in combination with double blind randomized split body safety assessment of C-TB Vs 2T.U, Tuberculin PPD RT23 SSI (PPD)”. The study included 1625 participants (SRC enrolled a total of 87) between the age of 1 month and 65 years that are suspected to be infected with TB. This study has been successfully completed but data are being analyzed.
New TB Drugs:
SRC is also conducting a four year phase III clinical trial titled “A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis”. This study is performed in collaboration with TB Alliance to evaluate a novel drug (PA-824) in shortening TB treatment and.
New TB Vaccines:
Currently, SRC is conducting a multi centre phase II clinical trial investigating a new TB vaccine, it is titled "A phase IIb, double-blind, randomised, placebocontrolled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in adults aged 18-50 years, living in a TB endemic region". The study is being conducted in collaboration with AERAS/GSK for a period of four years (August 2014 - August 2018) involving 3506 participants, of which SRC as a single site is enrolling 450 participants.
|
Declaration |
Declaration of interests:
No conflicts of interest were delacred.
|
| Application date: |
March 10, 2015 |
| Last updated: |
April 1, 2015 |
|
